Thursday, July 9, 2026

Drug profile · INN

acetaminophen

acetaminophen (ACEPHEN) is a cyclooxygenase inhibitor. Associated with Teva Pharma GmbH. Route of administration: rectal. Current US regulatory status: approved.

FDA: approved NMPA: clinical trials
US status approved
Patents linked 20
Pipeline programs 140
News articles 0
Drug details — acetaminophen
US status
approved
Class
Route
RECTAL
Patents
20
Programs
140
Data quality
0.89

Quick answer

acetaminophen (ACEPHEN) is a cyclooxygenase inhibitor. Associated with Teva Pharma GmbH. Route of administration: rectal. Current US regulatory status: approved.

Key facts

INN acetaminophen
Brand ACEPHEN
Mechanism Cyclooxygenase inhibitor
Target Fatty-acid amide hydrolase 1
Route RECTAL
Formulation CAPSULE

Mechanism of action

Cyclooxygenase inhibitor

Primary target: Fatty-acid amide hydrolase 1

Approval history

Authority Status Date
FDA approved
NMPA clinical trials

Pipeline programs

  1. 19356A Phase 3 · H. Lundbeck A/S · Migraine
  2. 9999 Phase 3 · United Therapeutics Europe · Non-Severe Pneumonia
  3. AXS-07 Phase 3 · Axsome Therapeutics · Migraine
  4. AXS-07 (MoSEIC meloxicam and rizatriptan) Phase 3 · Axsome Therapeutics · Migraine
  5. AXS-07 (meloxicam-rizatriptan) Phase 3 · Axsome Therapeutics · Migraine
  6. Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free) Phase 3 · Cumberland Pharmaceuticals · Acetaminophen Overdose
  7. Acetaminophen Phase 3 · S.L · Patency of the Ductus Arteriosus
  8. Atogepant, Placebo for atogepant tablets 60mg Phase 3 · AbbVie Deutschland GmbH · Migraine

Related & competitor drugs

  1. paracetamol Anandamide amidohydrolase inhibitor
  1. US 12410474

    Methods, kits, and devices for diagnosing, prognosing, and treating psychiatric disorders in a patient

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12377036

    Melanin hair dye with thickeners

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 12370267

    Inhibition of fibrosis and AF by TGF-beta inhibition in the posterior left atrium (PLA)

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 12351574

    Selective ligands for modulation of GIRK channels

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 12337019

    Vehicles for applying bacteria to skin, scalp, and hair

    Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 12331279

    Systems for producing cellular immunotherapeutics and methods of use thereof

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. WO 2025114603

    COMBINAISONS PHARMACEUTIQUES DESTINÉES À ÊTRE UTILISÉES DANS LE TRAITEMENT D'INFECTIONS FONGIQUES

    Expires Wed May 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 12319711

    Spherical nucleic acids with tailored and active protein coronae

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 12291533

    Substituted fused pyrimidine compounds and uses thereof

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 12281310

    Use of trinucleotide repeat RNAs to treat cancer

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 12264344

    Protein/oligonucleotide core-shell nanoparticle therapeutics

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 12258418

    Claudin18.2 binding moieties and uses thereof

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 12252522

    Myokines for treating cell proliferative and metabolic diseases and disorders

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 12252492

    Substituted fused pyrrolo-diazepinones and uses thereof

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 12247063

    Cell surface modification by coating with peptide amphiphiles (PAs)

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 12233081

    Hygromycin a compounds and methods of treating spirochete diseases

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 12233080

    Lipotechoic acid for immune modulation

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. US 12226444

    Compositions comprising peptides comprising variant kinesin light chain 1 and cell-penetrating peptides

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  19. US 12226410

    Methods for enhancing cellular clearance of pathological molecules via activation of the cellular protein ykt6

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  20. US 12214076

    Drug delivery vehicles for atherosclerosis nanomedicine

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is acetaminophen?

acetaminophen (ACEPHEN) is a cyclooxygenase inhibitor. Associated with Teva Pharma GmbH. Route of administration: rectal. Current US regulatory status: approved.

What is the brand name for acetaminophen?

ACEPHEN is a marketed brand name for acetaminophen. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of acetaminophen?

acetaminophen has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.